Ruxolitinib: prices and alternatives
Ruxolitinib is indicated for treatment of intermediate or high-risk myelofibrosis (primary or post-PV/ET), polycythemia vera in adults with inadequate response or intolerance to hydroxyurea, and steroid-refractory or steroid-dependent acute and chronic graft-versus-host disease.
4 products with this active ingredient from 2 manufacturers. Official prices from 3210 to 48749 EGP.
Every box with this active ingredient, cheapest first.
Informational only — may be inaccurate or incomplete. Don't rely on it medically; verify with a pharmacist.



